Cargando…

Ivacaftor in People with Cystic Fibrosis and a 3849+10kb C→T or D1152H Residual Function Mutation

Rationale: Ivacaftor’s clinical effects in the residual function mutations 3849 + 10kb C→T and D1152H warrant further characterization. Objectives: To evaluate ivacaftor’s effect in people with cystic fibrosis aged ≥6 years with 3849 + 10kb C→T or D1152H residual function mutations and to explore th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kerem, Eitan, Cohen-Cymberknoh, Malena, Tsabari, Reuven, Wilschanski, Michael, Reiter, Joel, Shoseyov, David, Gileles-Hillel, Alex, Pugatsch, Thea, Davies, Jane C., Short, Christopher, Saunders, Clare, DeSouza, Cynthia, Sullivan, James C., Doyle, Jamie R., Chandarana, Keval, Kinnman, Nils
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094270/ https://www.ncbi.nlm.nih.gov/pubmed/33095038 http://dx.doi.org/10.1513/AnnalsATS.202006-659OC

Ejemplares similares

Whole-exome sequencing accuracy in the diagnosis of primary ciliary dyskinesia
por: Gileles-Hillel, Alex, et al.
Publicado: (2020)

The clinical yield of bronchoscopy in the management of cystic fibrosis: A retrospective multicenter study
por: Gileles‐Hillel, Alex, et al.
Publicado: (2022)

Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization
por: Hubert, Dominique, et al.
Publicado: (2021)

Correction to: Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization
por: Hubert, Dominique, et al.
Publicado: (2021)

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849 + 10 kb C-to-T splicing mutation
por: Oren, Yifat S., et al.
Publicado: (2021)

A Case of Cystic Fibrosis With a Rare Mutation (3849 + 10 kbC > T) and Normal Sweat Chloride Levels
por: Ozdemir, Taha Resid, et al.
Publicado: (2015)

A Green Light for Stop Mutations
por: Cohen-Cymberknoh, Malena, et al.
Publicado: (2021)

Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review
por: Duckers, Jamie, et al.
Publicado: (2021)

Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States
por: Thorat, Teja, et al.
Publicado: (2021)

The CFTR Mutation c.3453G > C (D1152H) Confers an Anion Selectivity Defect in Primary Airway Tissue that Can be Rescued by Ivacaftor
por: Laselva, Onofrio, et al.
Publicado: (2020)

LRRC6 Mutation Causes Primary Ciliary Dyskinesia with Dynein Arm Defects
por: Horani, Amjad, et al.
Publicado: (2013)

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
por: Pilewski, Joseph M., et al.
Publicado: (2020)

A 1152 channel timing system for an electromagnetic calorimeter readout
por: Bonesini, M, et al.
Publicado: (1987)

1152. Characteristics of Patients with Invasive Infections Caused by Trichosporon asahii
por: Kim, Jinyeong, et al.
Publicado: (2020)

CCDC65 Mutation Causes Primary Ciliary Dyskinesia with Normal Ultrastructure and Hyperkinetic Cilia
por: Horani, Amjad, et al.
Publicado: (2013)

1152. Microbiology of Pediatric Neck Infections Based on Age and Anatomic Location
por: Dimo, Joana, et al.
Publicado: (2021)

Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study
por: Bell, Scott C., et al.
Publicado: (2019)

Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022)

HPLC Method for Determination of Enantiomeric Purity of a Novel Respiratory Fluoroquinolone: WCK 1152
por: Yeole, R. D., et al.
Publicado: (2008)

1152. Quantifying the health equity related public health impact of national immunisation programmes
por: Biundo, Eliana, et al.
Publicado: (2023)

Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

1152. Leveraging Human Factors Engineering to Optimize Low-level Disinfection of Bedside Medical Tools
por: Handy, Lori, et al.
Publicado: (2018)

1152. Implementation of Enhanced Data Surveillance Methods to Reduce Catheter-Associated Urinary Tract Infections
por: Ehni, Jordan, et al.
Publicado: (2019)

Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability
por: Vonk, Steffie E. M., et al.
Publicado: (2021)

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
por: Schwarz, Carsten, et al.
Publicado: (2021)

Assessment of Echinococcus multilocularis surveillance reports submitted in 2017 in the context of Commission Regulation (EU) No 1152/2011
por: Beltrán‐Beck, Beatriz, et al.
Publicado: (2017)

Bridging for lung transplantation with lumacaftor/ivacaftor
por: Pedersen, Søren Sperling, et al.
Publicado: (2018)

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)

Expanding clinical phage microbiology: simulating phage inhalation for respiratory tract infections
por: Ben Porat, Shira, et al.
Publicado: (2021)

Rho kinase inhibitors Y27632 and H1152 augment neurite extension in the presence of cultured Schwann cells
por: Fuentes, Erick O, et al.
Publicado: (2008)

The Advantage of a Total Knee Arthroplasty with Rotating Platform is Only Theoretical: Prospective Analysis of 1,152 Arthroplasties
por: Delport, H.P.
Publicado: (2013)

Retraction: Hydrogen Peroxide as an Effective Disinfectant for Pasteurella multocida. Yonsei Med J 2014;55:1152-6
por: Jung, In-Soo, et al.
Publicado: (2016)

Annual assessment of Echinococcus multilocularis surveillance reports submitted in 2018 in the context of Commission Regulation (EU) No 1152/2011
por: Ciubotaru, Ramona Mihaela, et al.
Publicado: (2018)

Assessing the Potency of the Novel Tocolytics 2-APB, Glycyl-H-1152, and HC-067047 in Pregnant Human Myometrium
por: Hossain, Md Reduanul, et al.
Publicado: (2022)

Miles J, Bailey SL, Obenaus AM, et al. Storage temperature determines platelet GPVI levels and function in mice and humans. Blood Adv. 2021;5(19):3839-3849.
Publicado: (2022)

Growth Hormone Therapy for Children With Duchenne Muscular Dystrophy and Glucocorticoid Induced Short Stature
por: Lavi, Eran, et al.
Publicado: (2021)

Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer
por: Azzariti, A, et al.
Publicado: (2011)

Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences
por: Rayford, Walter, et al.
Publicado: (2021)

Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor
por: Schneider, Elena K.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rppb6tko34oasrr9f9vfhro9h6